Cantor Fitzgerald Predicts PRQR FY2025 Earnings

ProQR Therapeutics (NASDAQ:PRQR) – Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for ProQR Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst J. Kim forecasts that the biopharmaceutical company will post earnings of ($0.36) per share for the year. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

A number of other research analysts have also issued reports on PRQR. Raymond James upgraded shares of ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the stock from $6.00 to $14.00 in a research report on Tuesday, October 29th. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Chardan Capital reiterated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a research report on Thursday, December 12th. Oppenheimer began coverage on ProQR Therapeutics in a report on Friday, January 10th. They set an “outperform” rating and a $15.00 target price on the stock. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $8.83.

ProQR Therapeutics Stock Performance

NASDAQ:PRQR opened at $2.17 on Wednesday. ProQR Therapeutics has a 52 week low of $1.61 and a 52 week high of $4.62. The firm’s 50-day simple moving average is $2.99 and its 200 day simple moving average is $2.55. The firm has a market cap of $177.25 million, a price-to-earnings ratio of -6.78 and a beta of 0.30.

ProQR Therapeutics (NASDAQ:PRQR) last posted its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01. The firm had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $4.75 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%.

Institutional Trading of ProQR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Ballentine Partners LLC bought a new position in shares of ProQR Therapeutics in the fourth quarter worth about $61,000. OneDigital Investment Advisors LLC increased its position in ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in ProQR Therapeutics by 14.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the last quarter. Finally, Privium Fund Management B.V. boosted its position in ProQR Therapeutics by 0.9% in the third quarter. Privium Fund Management B.V. now owns 5,632,388 shares of the biopharmaceutical company’s stock valued at $10,251,000 after buying an additional 51,663 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).